| Autor: |
Gangras P; Lilly Institute for Genetic Medicine, Eli Lilly and Company, Indianapolis, IN 46225, USA., Gelfanova V; Lilly Institute for Genetic Medicine, Eli Lilly and Company, Indianapolis, IN 46225, USA., Williams GD; Lilly Institute for Genetic Medicine, Eli Lilly and Company, Indianapolis, IN 46225, USA., Handelman SK; Lilly Institute for Genetic Medicine, Eli Lilly and Company, Indianapolis, IN 46225, USA., Smith RM; Lilly Institute for Genetic Medicine, Eli Lilly and Company, Indianapolis, IN 46225, USA., Debets MF; Lilly Institute for Genetic Medicine, Eli Lilly and Company, Indianapolis, IN 46225, USA. |
| Abstrakt: |
The SH-SY5Y neuroblastoma cells are a widely used in vitro model approximating neurons for testing the target engagement of therapeutics designed for neurodegenerative diseases and pain disorders. However, their potential as a model for receptor-mediated delivery and uptake of novel modalities, such as antibody-drug conjugates, remains understudied. Investigation of the SH-SY5Y cell surfaceome will aid in greater in vitro to in vivo correlation of delivery and uptake, thereby accelerating drug discovery. So far, the majority of studies have focused on total cell proteomics from undifferentiated and differentiated SH-SY5Y cells. While some studies have investigated the expression of specific proteins in neuroblastoma tissue, a global approach for comparison of neuroblastoma cell surfaceome to the brain and dorsal root ganglion (DRG) neurons remains uninvestigated. Furthermore, an isoform-specific evaluation of cell surface proteins expressed on neuroblastoma cells remains unexplored. In this study, we define a bioinformatic workflow for the identification of high-confidence surface proteins expressed on brain and DRG neurons using tissue proteomic and transcriptomic data. We then delineate the SH-SY5Y cell surfaceome by surface proteomics and show that it significantly overlaps with the human brain and DRG neuronal surface proteome. We find that, for 32% of common surface proteins, SH-SY5Y-specific major isoforms are alternatively spliced, maintaining their protein-coding ability, and are predicted to localize to the cell surface. Validation of these isoforms using surface proteomics confirms a SH-SY5Y-specific alternative NRCAM (neuron-glia related cell adhesion molecule) isoform, which is absent in typical brain neurons, but present in neuroblastomas, making it a receptor of interest for neuroblastoma-specific therapeutics. |
